Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Legal Issues Settled for Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Bethesda, MD-based Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) shares are off 5% after the company announced “meaningful progress” in resolving four lawsuits that were brought against it. The company announced that it expects to not pay any monetary damages.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

The Lawsuits

The lawsuit filed in a Maryland court included a variety of claims about alleged false reporting concerning results of the DCVax-Direct Phase I trial and the DCVax-L Phase III GBM trial, among other things.

Another lawsuit filed in Delaware and Maryland was a class action lawsuit on behalf of the Company and its shareholders naming Cognate, various Toucan entities, and NW Bio’s Board of Directors as defendants and seeking disgorgement of purportedly improper benefits and an unspecified amount of damages, among other relief.

The last lawsuit was filed in Maryland and was an amalgam of accusations detailed above.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) CEO Linda Powers stated “lawsuits like these can be a distraction from the important work of companies like ours. In my opinion, disposing of these cases is an important step forward in our vindication from the relentless and false campaign to discredit our science, our operations and our ethics, and hopefully helps remove what have been delaying obstacles in our path forward.  These resolutions come with no further price tag to shareholders, allowing us to focus our resources on the Company’s mission of providing our promising vaccines to as many solid tumor cancer patients as possible, at the earliest time possible.”

About Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)is a biotechnology company that develops personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The company has operations and sales in both the North America and Europe.

NWBO Stock Performance

The consensus one-year price target for NWBO stock is $5.00. However, today the shares hit a new low of $0.16. 10% of the shares float is held by short-sellers.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NWBO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Oncobiologics Inc. (NASDAQ:ONS) Receives $25 Million

Oncobiologics Inc. (NASDAQ:ONS)

Oncobiologics Inc. (NASDAQ:ONS) fell 5.94% after announcing the closure of a previously announced strategic partnership with GMS Tenshi holdings. The partnership provides the clinical stage biopharmaceutical company with the financial muscle needed to accelerate the development and commercialization of biosimilar candidates.

Oncobiologics Inc. (NASDAQ:ONS)

Purchase & Exchange Agreement

Oncobiologics Inc. (NASDAQ:ONS) is down by more than 50% for the year, having underperformed the overall industry for the better part of the year. The stock is currently trading in a downtrend and close to its 52-week low of $0.90 a share.

Pursuant to a Purchase and Exchange Agreement signed in September, GMS Tenshi is to receive Series A Convertible Preferred stock in exchange for $25 million. The investor has also been offered the option of acquiring warrants, for the purchase of an additional 16.8 million shares, with an aggregate exercise price of $15 million.

“This investment will also significantly enhance our commercialization abilities in emerging markets, along with our partnering and licensing capabilities. Our new collaborator shares in our vision is to accelerate the commercialization of the BioSymphony™ Platform and our pipeline, in the hopes of bringing affordable biologic drugs to patients around the world,” said CEO Pankaj Mohan.

Oncobiologics board has elected Faisal G. Sukhtian and Joe Thomas to the board of directors to fill vacancies left by Robin Smith Hoke and Donald J. Griffith. The two will represent GMS Tenshi under the Investors Rights Agreement.

Development-License Agreement

The two companies have also entered into a joint development and License Agreement. The agreement provides GMS Tenshi with rights to Oncobiologics Inc. (NASDAQ:ONS) two lead biosimilar assets ONS-1045 and ONS-3010, in emerging markets of China, India, and Mexico.

Oncobiologics Inc. (NASDAQ:ONS) plans to use net proceeds from the private placement for Phase 3 trials of its lead biosimilar candidate ONS-3010. The company has already completed Phase 1 clinical trials and is now preparing to enter Phase 3 trials next year. The candidate drug is being developed as HUMIRA biosimilar.

“Our objective is to help Oncobiologics prepare ONS-3010 so that it can be launched alongside other first-wave HUMIRA® Biosimilars with potentially improved tolerability compared to the originator product as reported in the successful Phase 1 trial,” GMS Tenshi In a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) Drops After Q3 Net Loss

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

Shares of Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) fell 3.4% after the pharmaceutical company reported a (-$2) million net loss. Basic and diluted net loss for the three months ended September 30, 2017, came in at (-$0.14) a share, compared to net loss of (-$0.41) reported last year.

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

RTTR Stock Performance

Despite a 42% year-over-year decrease in net loss, investors still pushed the stock lower in the market. Ritter Pharmaceuticals has underperformed the overall industry for the better part of the year. The stock is down by more than 80% for the year.

In defense of the company’s performance, Chief Executive Officer, Michael D. Step said they are committed and focused on the development of RP-G28, for the treatment of lactose intolerance. Plans are already underway to commence Phase 3 trials after a productive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).

RP-G28 Trials

During the quarter, Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) raised $23 million in an underwritten public offering. Net proceeds from the offering are to be used to finance the proposed Phase 3 trial in the first half of next year. The therapy has the potential to become the first FDA approved treatment for Lactose intolerance.

“With Phase 3 guidance from the FDA from our End of Phase 2 Meeting and our recent successful capital raise behind us, we have a clear regulatory pathway and we have sufficient funding to execute the first pivotal Phase 3 clinical trial of RP-G28 through data readout,” said Andrew J. Ritter President Ritter Pharmaceutical.

Ritter Pharmaceuticals Operating Costs

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)’s research and development expenses in the quarter totaled $0.9 million primarily attributable to Phase 2b/3 extension study fees of RP-G28 on Phase 3 program planning expenses. However, it was a decline from $2.3 million spent last year.

Total operating expenses in the quarter stood at $2 million compared to $3.5 million reported last year. The decrease was primarily as a result of a decrease in research and development expenses. Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) exited the quarter with cash and cash equivalent of $3.6 million. The cash balance also received a boost of $21 million from a public offering held last month.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RTTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Tries to Rebound

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock failed to hold early gains and end the trading session higher for the fourth day in a row. IDRA shares ended at $1.56 after gapping up to open the session at $1.72, which was also the high for the day. Volume was heavy – over three times the 30-day, daily average.

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

IDRA stock had plummeted on October 26, after Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced pricing a share offering at $1.50 – the previous close for IDRA shares was $2.03. The offering was for 33,333,334 shares of its common stock with a 30-day option to for the underwriters to purchase up to an additional 5,000,000 shares of common stock.

J.P. Morgan, Barclays, and Goldman Sachs & Co. LLC are the joint bookrunning managers on the $46.8 million transaction. H.C. Wainwright & Co. is acting as a co-manager on the transaction. Idera Pharmaceuticals Inc (NASDAQ:IDRA) intends to use the net proceeds to advance the development of IMO-2125 in its immuno-oncology program, for working capital, and for other general corporate expenses.

About Idera

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s development program focuses on boosting the immune system to play a more powerful role in fighting cancer, and ultimately increase the number of people who can benefit from immunotherapy. Idera invests in research and development, and works with investigators and partners to address the unmet needs of patients who are suffering from rare, life-threatening diseases.

IDRA Stock Performance

JP Morgan, Wedbush Securities, Piper Jaffray, and Baird all follow Idera Pharmaceuticals Inc (NASDAQ:IDRA) and rate the shares as a “Strong Buy”. The listed consensus one-year price target is $5.75.

Year-to-date ODRA shares are up only 4% – far below the sector’s performance. For the year, IDRA stock is up 0.65% but over the past week, after the company priced the offering at $1.50, shares have lost over 28% of their value.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has posted per share losses since 2012 (-$0.81) but the trend has been favorable and the loss for 2016 was just (-$0.30). Last year the company posted their first significant sales figure of $16.2 million. The downside for investors has been the annual dilution as outstanding shares have increased every year since 2012 when the number of outstanding shares was 27.64 million. But by the end of 2016, and prior to the most recent share offering, over 127 million shares were listed as outstanding.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Hit New Low

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares hit a new 52-week low of $0.90 on a volume figure of 1.2 million shares – almost four times the posted 30-day, daily average. EBIO shares have been on a steady slide since mid-September. In the past month, EBIO shareholders have lost over 37%.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a late-stage, clinical oncology company developing novel product candidates based upon their proprietary targeted protein therapeutics (TPTs) platform. Eleven Biotherapeutics TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule to achieve focused tumor cell killing.

On September 22, 2017 EBIO shares closed at $1.60 – around 60% above today’s closing price. That day Eleven Biotherapeutics Inc (NASDAQ:EBIO) announced that it had completed the manufacturing of all Vicinium for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. Accordingly, Eleven announced ending its large-scale manufacturing activities and redirection of resources towards the completion of its Phase 3 trial and preparing for discussions with the U.S. Food and Drug Administration (FDA) regardingthe submission of a Biologics License Application (BLA) for Vicinium in patients with NMIBC. This change included an impending reduction of headcount.

Eleven Biotherapeutics Performance

In 2012, EBIO shareholders experienced a per share loss of (-$13.91) that was followed in 2013 by a loss of (-$16.19). But in 2014, the per share loss shrank to ($-2.37), then shrank again in 2015. The trend continued and in 2016 the company posted a per share profit of ($0.09).

Sales have been lackluster and registered just $1 million for 2015 but Eleven Biotherapeutics posted sales of $30 million for 2016. Unfortunately, the number of outstanding shares has been increasing and diluting shareholder equity. In 2013 the number of outstanding shares was just 1.35 million. That number was reported at 21.08 million for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Drops After Pricing Offering

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares fell 14.7% after announcing the pricing of a previously announced public offering of 9 million shares on the Tel-Aviv Stock Exchange. The developer of placenta-based cell therapy products has priced the offering at $1.67 a share and expects gross proceeds of $15.1 million.

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

PSTI Investors Reaction

The accepted orders in the aggregate amount of $15.1 million after the offering became over-subscribed. The minimum share price consequently increased from $1.61 to $1.67 a share. The offering should close on or about December 31, 2017.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) plans to use net proceeds from the offering for research and product development. Part of the funds will also to be used to finance clinical trial activities, working capital, and for other general corporate purposes.

Investors reacted to the public offering pricing by pushing the stock lower. A point of concern is that the public offering was priced at a discount and that it could lead to further dilution of the stock. However, the stock continues to trade in an uptrend. The stock is up by more than 10% for the year.

PLX-R18 Development

The pricing of the public offering follows the Israel’s Ministry of Health approval of the company’s Phase 1 study of drug candidate PLX-R18. Pluristem Therapeutics Inc. (NASDAQ:PSTI) is investigating the drug candidate for the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation HCT. The U.S. Food and Drug Administration (FDA) has also approved the trial. In the United States, Pluristem is to recruit up to 30 patients for the trial.

“We’re very pleased with the Israeli Ministry of Health’s vote of confidence in our innovative therapies and efforts to provide treatments for a range of hematopoietic conditions, including insufficient recovery from hematopoietic stem cell transplants,” stated Zami Aberman, Pluristem Co-CEO, and Chairman

In addition, PLX-R18 is in late-stage development as a treatment for acute radiation syndrome (ARS). The cell therapy is designed to treat bone marrow that is unable to produce enough blood cells due to ARS. Pluristem Therapeutics Inc. (NASDAQ:PSTI) holds several patents that cover PLX-r18 for the treatment of impaired hematopoietic systems in case of a bone marrow transplant.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSTI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Bounces off Lows

Immune Design Corp (NASDAQ:IMDZ)

Shares of Immune Design Corp (NASDAQ:IMDZ) gained 12.2% ahead of their much-awaited financial results for the third quarter, ended September 30, 2017. The clinical stage immunotherapy company will release the results on November 1, 2017, after the close of the U.S. markets.

Immune Design Corp (NASDAQ:IMDZ)

Earnings Expectations

Investor confidence in the stock has taken a hit this month as seen by the stock shedding more than 50% in its market value. The stock has come under pressure following the pricing of an underwritten public offering of 19.5 million shares at a price of $4.10 a share. Investors pushed the stock lower after the company offered the shares at a discount to the market price.

Last quarter, the immunotherapy company reported a positive earnings surprise of 16.92% outpacing the consensus estimates of average earnings beat of 12.94%. A similar performance with Q3 financial results could result in the stock bouncing back from current trading levels.

Increased implied volatility on Immune Design Corp (NASDAQ:IMDZ) November options is already fuelling suggestions of a potential big move in either direction. Analysts at Zack’s research currently rate the stock as a ‘hold’.

Immune Design Pipeline

Progress on the company’s pipeline candidates should have an impact on the stock’s direction of trade going forward. The company’s lead candidate drugs are CMB305 for the treatment of solid tumor and G100 for the treatment of merkel cell carcinoma.

Immune Design is evaluating CMB305 both as a monotherapy and in combination with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Tecentriq. G100 is being developed on the GLAAS platform in collaboration with Merck for the treatment of patients with non-Hodgkin’s lymphoma (NHL).

The European Medicine Agency has granted G100 Orphan Drug Designation for the treatment of NHL. The designation is expected to accelerate its development while also guaranteeing market exclusivity for up to 10 years.

Immune Design Corp (NASDAQ:IMDZ) has the financial power to accelerate the development of the two candidate drugs given the pricing of the $80 million public offering.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Aviragen Therapeutics Inc (NASDAQ:AVIR) Shares Drop on Merger Announcment

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Shares of Aviragen Therapeutics Inc (NASDAQ:AVIR) are having their most volatile day in months after the biotechnology company announced that they were merging with Vaxart, Inc., a privately-held, clinical-stage company focused on developing oral recombinant vaccines. The merger will result in a combined company, Vaxart, Inc., focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Wouter Latour, M.D., Chief Executive Officer of Vaxart stated “This transaction gives us the opportunity to build on the positive Phase 2 challenge study results we announced recently for our influenza oral tablet vaccine, as well as the excellent results we obtained in the safety and immunogenicity studies with our norovirus vaccine.  Additionally, it will provide us access to Aviragen’s antiviral assets, including their BTA074 Phase 2 program for the treatment of condyloma caused by HPV, which is on track to complete enrollment this quarter and to report top-line safety and efficacy data in the second quarter of 2018.”

Deal Details

The exchange ratio was determined by assigning $60 million in value to Aviragen Therapeutics Inc (NASDAQ:AVIR) for its financial and clinical assets and $90 million in value for Vaxart’s assets. On a pro forma basis, after giving effect to the number of shares of Aviragen common stock issued in the merger, Vaxart’s securityholders will own approximately 60% of the combined company and Aviragen Therapeutics Inc (NASDAQ:AVIR) shareholders will own approximately 40% of the combined company.

AVIR Stock Review

AVIR shares ended Friday at $0.83 then gapped up this morning to open at $0.96 on the merger news. The shares went on to hit an inter-day high of $1.08 before sellers came in a pushed the price down to a low of $0.67. Currently shares are trading around the $0.70 handle.

AVIR shares have done well since they hit a 52-week low early this past summer at $0.43. For the month they are up over 27% and up for the quarter by a whopping 50%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVIR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

pSivida Corp. (NASDAQ:PSDV) Turns to Strategic Collaboration

pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. (NASDAQ:PSDV) was unchanged in Friday’s trading session, days after announcing a strategic collaboration with Nicox S.A. The collaboration seeks to enhance the development of a sustained-release drug that can lower intraocular pressure in patients with glaucoma or Ocular Hypertension.

pSivida Corp. (NASDAQ:PSDV)

PSDV Stock Performance

pSivida Corp. (NASDAQ:PSDV) shares are currently trading near all-time lows, the stock having been under immense selling pressure since June. Over the past four months, the stock has shed more than 50% in market value as it continues to trade in a downtrend. The company has since turned to strategic collaboration as it seeks to reinvigorate its prospects.

Nicox-pSivida Collaboration

Pursuant to the agreement, the two companies are to collaborate in the selection of NO-donating products from Nicox’s research portfolio, which are to be combined with pSivida’s sustained release drug technology.

“Combining this novel approach to IOP lowering with our bio erodible, a sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma,” said CEO, Nancy Lurker.

pSivida Corp. (NASDAQ:PSDV) has the responsibility of taking care of initial development activities of ocular insert formulations, for which it will receive undisclosed payments from Nicox. Under the terms of the agreement, the two companies may proceed with further development including non-clinical studies needed to generate pre-clinical data.

Nicox is to cater for any expenses that arise from incremental development activities for each product selected to progress into development. The two will negotiate a license agreement for any product that comes out of the collaboration.

Glaucoma Partnership

In addition, pSivida Corp. (NASDAQ:PSDV) has signed an agreement with a major pharmaceutical company for the development of two glaucoma drugs using its proprietary release technology. Under the terms of the agreement, the company is to receive, upfront payments of $750,000 for initial development. Additional payment totaling $200,000 could come into play depending on certain milestones.

“A key focus for pSivida during 2017 is to expand the number of development collaboration agreements with other drug manufacturers and this is the second such agreement during 2017. This agreement extends the strong working relationship between the two organizations,” Lurker in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PSDV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX) Bounce back Gathers Momentum

Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX) rebound from this year’s lows of $0.26 a share continued in Friday’s trading session, as its shares gained 3.11% to end the week at $0.5336. However, the stock is still down for year-to-date after losing more than 50% in market value since January.

Repros Therapeutics Inc. (NASDAQ:RPRX)

FDA Clinical Hold Debacle

Investor confidence in Repros Therapeutics Inc. (NASDAQ:RPRX) took a hit in June after the U.S. Food and Drug Administration (FDA) instituted a clinical hold on the company’s Proellex program for the treatment of uterine fibroids. According to the agency, Repros Therapeutics Inc. (NASDAQ:RPRX) will have to conduct a much larger clinical study if the FDA is to lift the partial clinical hold. A point of concern to investors is that the additional requirements could end up being expensive and time-consuming.

This is not the first time that the biopharmaceutical company has found itself at odds with the FDA with regards to the development of Proellex. In 2009, the FDA placed the program under clinical hold, but later allowed it to continue under partial clinical hold with low oral dosage.

Repros Therapeutics Inc. (NASDAQ:RPRX) is also evaluating Proellex in its Phase IIb study for uterine fibroids by vaginal delivery. The company says it plans to increase its focus on this study given that it does not have clinical hold issues.

“Clinical work done to date suggests that vaginal delivery of telapristone acetate has the potential to yield good efficacy with significantly lower systemic blood levels. Furthermore, we intend to leverage drug delivery technology that could offer to dose less frequently than once per day,” said CEO, Larry Dilaha.

Q2 Net Loss

The Texas-based biopharmaceutical company reported a net loss of (-$2.2) million or (-$0.08) a share for the three months ended June 30, 2017, compared to a net loss of (-$4.3) million a year ago. The decline was primarily due to a decrease in clinical development expenses related to Proellex and enclomiphene product candidates.

Repros Therapeutics Inc. (NASDAQ:RPRX)’s net loss for the first six months of the year stood at (-$8.1) million or (-$0.30) a share, compared to a net loss of (-$9.1) million for the corresponding period last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.